Agents and methods for the prevention or treatment of H. pylori infections

Patent metadata

Field	Value
Publication number	US-12558425-B2
Application number	US-202217934113-A
Country	US
Kind code	B2
Filing date	Sep 21, 2022
Priority date	Jul 20, 2016
Publication date	Feb 24, 2026
Grant date	Feb 24, 2026

Abstract

The present invention relates to inhibitors of the interaction between H. pylori HopQ and a member of the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family as well as to immunogenic compositions based on H. pylori HopQ. The present invention further relates to the use of the inhibitors and immunogenic compositions for preventing or treating a disease or disorder caused by or associated with H. pylori.

First claim

The invention claimed is:

1 . A method of immunizing against or treating an H. pylori infection, comprising administering to a subject in need thereof a therapeutically effective amount of:
(i) the immunogenic composition comprising: at least one isolated (poly-)peptide comprising the amino acid sequence of H. pylori HopQ, or an immunogenic fragment thereof, wherein the immunogenic fragment comprises an extracellular domain of H. pylori HopQ selected from the group consisting of: an insertion domain of H. pylori HopQ; loop A of H. pylori HopQ; loop B of H. pylori HopQ; loop C of H. pylori HopQ; loop D of H. pylori HopQ; and an immunogenic variant of the isolated (poly-)peptide having at least 90% sequence identity to one of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 15; or (ii) a composition comprising an isolated HopQ fragment comprising a HopQ AD , wherein the HopQ AD has an amino acid sequence corresponding to residues 37 to 463 of SEQ ID NO: 1.

2 . The method according to claim 1 , wherein the H. pylori infection causes a gastroduodenal disorder.

3 . The method according to claim 2 , wherein the gastroduodenal disorder is selected from the group consisting of gastritis, chronic gastritis, gastric or duodenal ulcer, stomach cancer and MALT lymphoma.

4 . The method according to claim 1 , wherein the isolated HopQ fragment itself or an immune response raised against the fragment inhibits an interaction between H. pylori HopQ and a member of the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family.

Assignees

• Univ Muenchen Tech
• Max Planck Gesellschaft

Inventors

• Javaheri Anahita
• Kruse Tobias
• Gerhard Markus
• Singer Bernhard B
• Hornburg Daniel
• Remaut Han
• Mann Matthias
• Meissner Felix
• Backert Steffen

Classifications

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P31/04

  Antibacterial agents · CPC title